Results 81 to 90 of about 96,322 (259)

Combinatorial Metabolic Engineering of Alkane Biosynthesis in the Osmotolerant Yeast Debaryomyces hansenii CBS 767

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Debaryomyces hansenii is a yeast with diverse potential applications like producing oleochemicals from biomass. Yet, combinatorial metabolic engineering in D. hansenii is limited because, like many nonconventional organisms, key genomic data and genetic elements are missing. Here, we report phenotypic characterization, genomic integration loci,
Zekun Li   +3 more
wiley   +1 more source

Need for longitudinal studies to assess the real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma – Authors´ reply

open access: yesThe Lancet Regional Health. Europe, 2022
Benedikt Fritzsching   +7 more
doaj   +1 more source

Pharmacokinetic-Based Drug–Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review

open access: yesDrug Design, Development and Therapy, 2020
Dehua Zhao,1 Jing Chen,1 Mingming Chu,2 Xiaoqing Long,1 Jisheng Wang1 1Department of Clinical Pharmacy, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang 621000, People’s Republic of China; 2Department of Clinical Pharmacy ...
Zhao D, Chen J, Chu M, Long X, Wang J
doaj  

The Effect of Tribulus Terrestris Extract on Hepatic Complications Due to the Gelofen Consumption in Adult Female Rats [PDF]

open access: yesJournal of Advanced Biomedical Sciences, 2016
Background & Objective: Gelofen is one of the anti-inflammatory drugs which is used to relieve the pain and reduce the inflammations. This drug has side effects on body's tissues.
Leila Hejazi, Seyed Ebrahim Hosseini
doaj  

Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia [PDF]

open access: yesExploration of Targeted Anti-tumor Therapy
Aim: This study aimed to evaluate the real-world efficacy and safety of lorlatinib in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior ALK tyrosine kinase ...
Sergey V. Orlov   +9 more
doaj   +1 more source

Talking the Walk: ESG Discourse as Strategic Dynamic Capability

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT Conventional wisdom suggests that firms must “walk the talk” on sustainability. In turbulent institutional environments, however, talking increasingly becomes part of the walk, as organizations use sustainability discourse to construct and maintain legitimacy.
Floriana Luisi   +1 more
wiley   +1 more source

Treatment with the SQ tree sublingual immunotherapy tablet is safe and well tolerated in real‐life

open access: yesClinical and Translational Allergy
Background The SQ tree sublingual immunotherapy (SLIT)‐tablet is authorised for treatment of allergic rhinoconjunctivitis with or without asthma in trees of the birch homologous group in 21 European countries.
Oliver Pfaar   +13 more
doaj   +1 more source

A Case of Adjuvant Brigatinib in a Patient with ALK-rearranged R0 Resected Oligometastatic Lung Cancer [PDF]

open access: yes
Anaplastic lymphoma kinase (ALK) rearrangement is detected at a low rate in non-small cell lung cancer (NSCLC). Patients with ALK rearrangements have poor responses to conventional cytotoxic chemotherapy.
Nalan Akyürek   +4 more
core   +1 more source

Corporate Indigenous Stakeholder Engagement in the Sustainability Reporting: Evidence From the Australian Mining Industry

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT Given the growing pressure for indigenous stakeholder engagement, this paper explores the extent and nature of indigenous stakeholder engagement disclosures in the sustainability reporting of Australian mining companies. Drawing on stakeholder theory and legitimacy theory, this study explores how large Australian mining companies disclose ...
Md. Moazzem Hossain   +5 more
wiley   +1 more source

Dual ALK/ROS1 Positivity in Lung Adenocarcinoma: A Case of Complete Response to Lorlatinib

open access: yesJournal of Oncological Sciences
Objective: Anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) rearrangements are unique, mutually exclusive mutations that drive non-small cell lung cancer.
Neslihan ÖZYURT, Aykut TURHAN
doaj   +1 more source

Home - About - Disclaimer - Privacy